

Research workbook

2020

France

Contributors

Maitena Milhet, Isabelle Michot (OFDT)

2020 National report (2019 data) to the EMCDDA by the French Reitox National Focal Point

Supervision: Julien Morel d’Arleux

Coordination and editorial: Marc-Antoine Douchet

Contribution to the workbooks

- 1. *Drug Policy*: Cristina Díaz-Gómez, Marc-Antoine Douchet
- 2. *Legal Framework*: Caroline Protais, Marc-Antoine Douchet, Cristina Díaz-Gómez
- 3. *Drugs*: Olivier Le Nézet, Magali Martinez, Clément Gérome, Michel Gandilhon
- 4. *Prevention*: Carine Mutatayi
- 5. *Treatment*: Christophe Palle, Anne-Claire Brisacier
- 6. *Best Practice*: Carine Mutatayi, Anne-Claire Brisacier, Christophe Palle
- 7. *Harms and Harm Reduction*: Anne-Claire Brisacier, Cristina Díaz-Gómez, Magali Martinez
- 8. *Drug Market and Crime*: Michel Gandilhon, Magali Martinez, Caroline Protais, Victor Detrez
- 9. *Prison*: Caroline Protais, Anne-Claire Brisacier, Christophe Palle, Julien Morel d’Arleux
- 10. *Research*: Isabelle Michot, Maitena Milhet

Proofreading (French version): Julien Morel d’Arleux (OFDT); Nicolas Prisse, president of the Interministerial Mission for Combating Drugs and Addictive Behaviours, and the project managers of the MILDECA

Proofreading (English version): Anne de l’Eprevier

Bibliographic references: Isabelle Michot

Legal references: Anne de l’Eprevier

Table of Contents

T0.	Summary	3
T1.	Drug-related research	4
T2.	Trends (Not applicable for this workbook)	8
T3.	New developments	8
T4.	Additional information	17
T5.	Sources and methodology	17

T0. Summary

Please provide an abstract of this workbook (target: 500 words) under the following headings: National profile

In this section please summarise the most relevant information included in the following sections, namely:

- A description of national profiles:
 - main entities financing research on drugs;
 - main research institutions involved in the research on drugs;
 - if applicable, the role of the national drug observatory in the implementation, execution or coordination of drug-related research activities;
 - main national or regional scientific journals publishing drug related research and
 - main drug-related research projects, (planned or ongoing)
- A description of research priorities (if available)
 - drug-related priorities defined in national/regional drug policy;
 - the role of drug-related research in national drug policy documents;
 - new topics emerging in drug-related research in your country (either in governmental or non-governmental research)

National profile

In France, the Ministry of National Higher Education, Research and Innovation (MENESR) designs, coordinates and implements national policy on research and innovation. Two primary academic organisations, the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM), cover a wide range of research areas, from neurosciences, through public health and clinical research to social sciences.

The French National Focal Point (OFDT) is the main body involved in drug-related data collection, studies and network development. It collaborates extensively with national and European drug-related research teams. Dissemination of data and research results are also part of its mandate, together with publishing in national and international scientific journals, and promoting the use of research results in practice and policymaking.

The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA) is the central structure close to the Prime Minister responsible for coordinating governmental action in the drugs field. Part of its role is to promote and fund drug-related research.

New development (including a description of research priorities, if available)

In line with previous government plans, developing research and observation in the field of addictions is key in order to provide information on the implementation of public policies. It represents therefore one of the 6 major challenges included in the 2018-2022 National Action plan on Addictions (MILDECA 2018). The measures to be implemented focus on two main priorities:

- 1) Bringing science, political policy-making and citizens closer together;
- 2) Extending knowledge in all areas of public action.

In order to improve links between the scientific community, policymakers and citizens, the plan aims to increase places and times for meetings about spreading knowledge on addiction, both nationally and regionally. The importance of the focal point (OFDT) is underlined as it enjoys ideal positioning for speeding up transfer of knowledge and its appropriation by decision-makers, professionals and citizens.

Linked to the priority to “bring science, policy-making and citizens closer together”, the MILDECA also wants to create an interministerial forum for discussion categorised by major policy area (science and prevention, science and treatment, science and judicial response and science and counter-trafficking). This forum will focus on planning interministerial meetings to improve programming and dissemination of knowledge. This will involve sharing existing literature with public stakeholders and working with them to determine the gaps in existing research and the necessary studies to be developed in order to determine appropriate

intervention measures. Finally, the MILDECA will strive to share the results of this work with the relevant policymakers in order to help them elaborate relevant public responses based on strong scientific data (for example, the meeting organised by the MILDECA on the report "addictions and new technologies" carried out by Pr Reynaud).

The plan highlights several key areas where new knowledge is required: prevalence of use among vulnerable groups (people with disabilities, people living in poverty, people subject to a court order, migrants), influence of environmental factors and available preventive and healthcare supplies on the dependence and treatment trajectories, individual vulnerability factors, gender specific factors, etc.

In order to prevent addictive behaviours, emphasis is placed on carrying out intervention research in schools and workplaces. The plan also promotes the development of knowledge related to marketing strategies that influence how the risks of using are perceived among young people. Such information is required in order to deconstruct the discourse conveyed by industrialists and to put in place appropriate responses.

To better reduce risks and improve care and access to care, the plan confirms the need to support clinical and therapeutic research by encouraging a transversal and collaborative approach. Evaluating medico-social and harm reduction interventions is also valued.

Moreover, in terms of questioning the effectiveness of criminal solutions, the authorities stress the need to develop evaluative research in this field in order to encourage solutions to develop the most promising judicial measures. As regards research relating to drug supply, the plan notably encourages improved monitoring of new psychoactive substances and studies on the changes in supply.

T1. Drug-related research¹

The purpose of this section is to

- Describe the organization of drug-related research in your country
- Provide a summary of specific resources on drug-related research available in your country
- Update the available information already provided to the EMCDDA (workbook will be pre-filled).

T1.1. Please update the main drug-related research institutions/associations/bodies (public or private) in your country. Please provide links, also to pages in English, if available.

- Centre National de la Recherche Scientifique (CNRS):
<http://www.cnrs.fr/index.php/en>
- Conservatoire National des Arts et Métiers (CNAM):
<http://the.cnam.eu/>
- École des Hautes Études en Santé Publique (EHESP):
<http://www.ehesp.fr/en/>
- École des Hautes Études en Sciences Sociales (EHESS):
<https://www.ehess.fr/en>

¹ "Drug-related research involves performing a study on illicit drugs, which may involve a range of disciplines, through the use of scientifically accepted methods and procedures, in order to test a hypothesis or answer a specific question." (EMCDDA, 2012 [Drug-related research in Europe: recent developments and future perspectives](#))

- Fédération Nationale des Observatoires Régionaux de la Santé (FNORS):
<http://www.fnors.org/index.html>
- Fondation Nationale des Sciences Politiques (FNSP):
<http://www.sciencespo.fr/en/home>
- Institut de Recherche en Santé Publique (GIS-IReSP):
<http://www.iresp.net/>
- Institut de Recherche pour le Développement (IRD):
<http://en.ird.fr/ird.fr>
- Institut National de la Recherche Agronomique (INRA):
<http://www.inra.fr/en>
- Institut National de la Santé et de la Recherche Médicale (INSERM):
<http://english.inserm.fr/>
- Observatoire Français des Drogues et des Toxicomanies (OFDT):
<https://en.ofdt.fr/>
- Santé publique France (SpF)
<https://www.santepubliquefrance.fr/>

T1.2. Please update the main institutions/associations/bodies/programmes (public or private) funding drug-related research in your country.
Please provide links, also to pages in English, if available.

- The Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA: <http://www.drogues.gouv.fr/page-simple/mildeca-interministerial-mission-combating-drugs-and-addictive-behaviours>) is the central structure responsible to the Prime Minister for coordinating governmental action in the drugs field. Part of his role is to promote and fund drug related research. In line with the National Drug Action Plan 2018-2022, the MILDECA supported new annual [calls for proposals](#) and extended collaborations with research organizations/universities and with the ANR. It also promoted clinical research networks and dissemination initiatives towards the scientific community and policy makers.
- The Ministry of Higher Education, Research and Innovation (<http://www.enseignementsup-recherche.gouv.fr/>) designs, coordinates and implements national policy on research and innovation. A large scope of research areas ranging from neurosciences, through public health and clinical research to social sciences is mainly covered by two major academic operators: the National Centre for Scientific Research (CNRS) and the National Institute for Health and Medical Research (INSERM).
- The French Research Agency (*Agence Nationale de la Recherche* – ANR: <http://www.agence-nationale-recherche.fr/en/project-based-funding-to-advance-french-research/>) is in charge of programming national research and innovation. The agency establishes the thematic priorities of research and allocates the resources. Every year, the agency launches calls for tenders covering a large spectrum of scientific areas.
- The Ministry of Health (<http://www.sante.gouv.fr/>) funds, in specific years, clinical projects on addiction treatment in hospitals (under the programme “*Programme Hospitalier de Recherche Clinique*” - PHRC). It also funds studies on specific

populations of drug users, interventions (prevention, treatment, harm reduction) or legal disposition.

- The National Research Agency on AIDS (*Agence Nationale de Recherche sur le Sida* – ANRS: <http://www.anrs.fr/>) and the French Public Health Agency (*Santé publique France*: <https://www.santepubliquefrance.fr/>) implement regular surveys and research projects on the links between injecting drug use and infectious diseases (mainly HIV and HCV).
- The French National Cancer Institute (*Institut national du cancer* – INCa: <http://en.e-cancer.fr/>) is the preeminent health and science agency in charge of cancer control in France, created in 2004. It reports to the ministries for Health and for Research. About half of its budget (€100 million) is allocated to research funding. Each year, the Institute organises more than fifteen competitive calls for proposals in the areas of research, public health, cancer care organisation and patient information.
- NGOs and foundations (such as the *Fondation de France*) representing practitioners, users and companies (alcohol suppliers, tobacco industry and pharmaceutical laboratories) also regularly fund surveys and research project in these areas.

T1.3. Please update the list of the main national scientific journals where drug-related research is published in your country.
Please provide links, also to pages in English, if available.

Name	Topic	Language	Abstract
Actualité et Dossier en Santé Publique https://www.hcsp.fr/explore.cgi/adsps?ae=adsps&menu=11	Public Health	French	French
Addiction(s) : recherches et pratiques https://www.federationaddiction.fr/productions/revue/	Treatment	French	French
Alcoologie et Addictologie http://www.alcoologie-et-addictologie.fr/ http://www.alcoologie-et-addictologie.fr/index.php/aa/user/setLocale/en_US?source=%2Findex.php%2Faa	Treatment	French, English	English
Annales Médico-psychologiques, revue psychiatrique https://www.sciencedirect.com/journal/annales-medico-psychologiques-revue-psychiatrique	Psychiatry	French, English	English
Archives des Maladies Professionnelles et de l'Environnement https://www.sciencedirect.com/journal/archives-des-maladies-professionnelles-et-de-lenvironnement	Treatment	French	English
Bulletin de l'Académie Nationale de Médecine https://www.sciencedirect.com/journal/bulletin-de-lacademie-nationale-de-medecine	Public Health	French	English
Bulletin Épidémiologique Hebdomadaire https://www.santepubliquefrance.fr/revues/beh/bulletin-epidemiologique-hebdomadaire	Epidemiology and public health	French	English
Cahiers de la Sécurité et de la Justice https://inhesj.fr/publications/cahiers-de-la-securite-et-de-la-justice	Sociology and political science	French	English
Le Courrier des Addictions https://www.edimark.fr/courrier-addictions	Addiction all topics	French	English

Déviante et Société https://www.caim.info/revue-deviance-et-societe.htm https://www.caim-int.info/journal-deviance-et-societe.htm	Sociology and political science	French	English
L'Encéphale https://www.sciencedirect.com/journal/lencephale	Treatment	French	English
Médecine/sciences https://www.medecinesciences.org/ https://www.medecinesciences.org/en/	Health	French	English
Politix, revue des sciences sociales du politique https://www.caim.info/revue-politix.htm https://www.caim-int.info/journal-politix.htm	Human and social sciences	French	English
La Presse Médicale https://www.sciencedirect.com/journal/la-presse-medicale	Health	French	English
Psychotropes, Revue internationale des toxicomanies et des addictions https://www.caim.info/revue-psychotropes.htm	Treatment	French	English
Revue d'Épidémiologie et de Santé Publique https://www.sciencedirect.com/journal/revue-depidemiologie-et-de-sante-publique	Epidemiology and public health	French, English	English
Revue Française des Affaires Sociales https://www.caim.info/revue-francaise-des-affaires-sociales.htm https://www.caim-int.info/journal-revue-francaise-des-affaires-sociales.htm	Human and social sciences	French	English
Revue Française de Sociologie https://www.caim-int.info/revue.php?ID_REVUE=E_RFS https://www.caim-int.info/journal-revue-francaise-de-sociologie.htm	Sociology	English, French	English
La Revue de médecine interne https://www.em-consulte.com/produit/revmed	Medical Sciences	French	English
La Revue du Praticien - Monographie http://www.larevedupraticien.fr/revue	Medical Sciences	French	English
Santé Publique https://www.caim.info/revue-sante-publique.htm https://www.caim-int.info/journal-sante-publique.htm	Epidemiology and public health	French	English
Sciences Sociales et Santé https://www.jle.com/fr/revues/sss/revue.phtml http://www.jle.com/en/revues/sss/revue.phtml	Human and social sciences	French, English	English
Sociologie https://www.caim.info/revue-sociologie.htm (copy/paste this link) https://www.caim-int.info/revue.php?ID_REVUE=E_SOCIO	Sociology	French	English
Thérapie https://www.sciencedirect.com/journal/therapies	Treatment	French, English	English
Toxicologie Analytique et Clinique https://www.sciencedirect.com/journal/toxicologie-analytique-et-clinique	Toxicology	French, English	English

- T1.4. Please update the list of drug-related research relevant websites/resources you would like us to include in your research country profile.
Please provide links, also to pages in English, if available.

T2. Trends (Not applicable for this workbook)

T3. New developments

The purpose of this section is to provide information on any notable or topical developments observed in drug-related research in your country **since your last report**.

T1 is used to establish the baseline of the topic in your country. Please focus on any new developments here.

If information on recent notable developments have been included as part of the baseline information for your country, please make reference to that section here. It is not necessary to repeat the information.

- T3.1. Please update the list of the main drug-related, recent/on-going since your last report studies/research projects in your country. Please provide links, also to pages in English, if available. If possible, classify each study/research project under one of the following categories:
- (1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research);
 - (2) Population based and clinical epidemiology (including site surveys, ethnographic studies and acute toxicity studies);
 - (3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research);
 - (4) Supply, supply reduction and crime;
 - (5) Drug policy (including laws, economic issues and strategies);
 - (6) Other topics.
- If it is not possible to identify the main drug-related on-going studies/research projects in your country, please provide a list of the most relevant current bibliographic references.

In November 2018, the MILDECA-OFDT Scientific Prize, which rewards promising research on drugs and addiction, was awarded to two scientists who are renowned nationally and internationally for their research projects. They mainly worked on helping better understand young people's pathway to using and on improving prevention interventions in this field: Maria Melchior, an epidemiologist and research director at INSERM, and Mickaël Naassila, a physiology professor and director of INSERM's research group on alcohol and drug dependence.

Research on drugs and addictive behaviour is becoming increasingly more important in the French scientific landscape. Between 2010 and 2016, the number of publications on drugs and addiction increased by 30%. Over the same period, investment in public research on addictive behaviour steadily increased (from 13.5 to 17 million euros: 26% increase).

In 2019 the Fund for Combatting Tobacco was extended to all substance-related addictions and therefore became the Fund for Combatting Addiction. This changes, among other things, the volume and distribution of resources dedicated to research with a substantial annual sum intended to "support knowledge sharing, innovation, applied research and the evaluation of care and prevention actions".

The *Fonds Addictions* (a fund to combat psychoactive substance addiction) was implemented by [decree no. 2019-622 of 21 June 2019](#) on the psychoactive substances addiction fund. The [legislative order of 2 August 2019](#) established the list of beneficiaries and the amounts allocated by this Fund for Combatting Addiction for 2019, amounting to €120 million. It is managed by the French National Health Insurance Fund and includes €46 million invested in

aid to stop smoking, €32 million to support regional projects, €18 million for national civil society projects, €11 million to set up social marketing campaigns, and €13 million invested in research. The Fund for Combatting Addiction therefore provides both funding for actions (which may be subject to evaluation) and an amount specifically earmarked for research (licit and illicit substances).

In this context, a sum of €400,000 has been paid to the French Monitoring Centre for Drugs and Drug Addiction to carry out new studies. The text also establishes a €5,000,000 sum granted for a call for projects by the IReSP supporting applied research programmes and the evaluation of interventions to combat addictions linked to psychoactive substances. The aim of the call for projects was to support research in the field of addiction, with priority on alcohol, tobacco and cannabis, but also on other psychoactive substances (other narcotics, products for therapeutic use). At the end of 2019, 21 research projects were selected for funding. They cover a continuum of scientific disciplines from the basic sciences to intervention research, the humanities and social sciences, economics, epidemiology and other public health disciplines. In addition, public authorities continue to support the training of new researchers in the field of addictions through the renewed awarding of doctoral (PhD) grants.

Bibliography 2019-1st quarter 2020

(1) Basic biological, neurobiological and behavioural research (including aetiological and addictive behaviour research)

Acier, D. (2019). L'addiction comme rempart à la dépression [Addiction, an anti-depressive struggle] (with English abstract). Psychologie Clinique (48) 40-49.

Allard, M., Leclercq, M. and Labat, L. (2019). La toxicologie du GHB et de ses précurseurs [Toxicology of GHB and its precursors] (with English abstract). Revue Francophone des Laboratoires 2019 (517) 36-42.

Alvarez, J.C., Simon, N., Larabi, A., Ribot, M., Derridj-Ait-Younes, N. and Hartley, S. (2020). Relation pharmacocinétique/pharmacodynamique entre la concentration sanguine de tétrahydrocannabinol et l'aptitude à conduire un véhicule chez des consommateurs occasionnels ou chroniques de cannabis [Pharmacokinetic/pharmacodynamic relationship between tetrahydrocannabinol blood concentration and ability to conduct a vehicle in chronic and occasional cannabis consumers] (with English abstract). Bulletin de l'Académie Nationale de Médecine 204 (5) 477-485.

Arbouche, N., Raul, J.-S., Garnier, D., Kintz, P. and Ameline, A. (2019). Testing for AB-PINACA in human hair: Distribution in head hair versus pubic hair. Drug Testing and Analysis 11 (4) 610-616.

Benturquia, N., Chevillard, L., Poiré, C., Roussel, O., Cohier, C., Declèves, X. *et al.* (2019). Is the 3,4-methylenedioxypropylvalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. Psychopharmacology 236 (3) 891-901.

Bouvarel, T., Delaunay, N. and Pichon, V. (2020). Selective extraction of cocaine from biological samples with a miniaturized monolithic molecularly imprinted polymer and on-line analysis in nano-liquid chromatography. Analytica Chimica Acta 1096 89-99.

Derouiche, L. and Massotte, D. (2019). G protein-coupled receptor heteromers are key players in substance use disorder. Neuroscience and Biobehavioral Reviews 106 73-90.

Dervaux, A. (2019). Comment le cannabis peut favoriser les troubles psychotiques : conséquences, dépistage et prise en charge [How cannabis can trigger psychotic disorders : Consequences, detection, and treatment] (with English abstract). L'Information Psychiatrique 95 (8) 672-678.

- Dufлот, T., Vasse, M., Guillerme, J., Schrapp, A., Mory, C., Imbert, L. *et al.* (2019). Interest of adjusting urine cannabinoids to creatinine level to monitor cannabis cessation therapy in heavy smokers with psychiatric disorders. Drug Testing and Analysis 11 (9) 1453-1459.
- Fabresse, N., Aouad, H., Knapp, A., Mayer, C., Etting, I., Larabi, I.A. *et al.* (2019). Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous detection of 10 illicit drugs in oral fluid collected with FLOQSwabs™ and application to real samples. Drug Testing and Analysis 11 (6) 824-832.
- Fabresse, N., Becam, J., Carrara, L., Descoeur, J., Di Mario, M., Drevin, G. *et al.* (2019). Cannabinoïdes et thérapeutique [Cannabinoids and therapeutics] (with English abstract). Toxicologie Analytique et Clinique 31 (3) 153-172.
- Fabresse, N., Larabi, I.A., Stratton, T., Mistrik, R., Pfau, G., Lorin de la Grandmaison, G. *et al.* (2019). Development of a sensitive untargeted liquid chromatography-high resolution mass spectrometry screening devoted to hair analysis through a shared MS2 spectra database: A step toward early detection of new psychoactive substances. Drug Testing and Analysis 11 (5) 697-708.
- Franchitto, N. (2020). Complications somatiques du cannabis [Cannabis use and somatic consequences] (with English abstract). La Revue du Praticien 70 (1) 69-77.
- Girardeau, P., Navailles, S., Durand, A., Vouillac-Mendoza, C., Guillem, K. and Ahmed, S.H. (2019). Relapse to cocaine use persists following extinction of drug-primed craving. Neuropharmacology 155 185-193.
- Hazif-Thomas, C., Chandès, G. and Thomas, P. (2019). Addiction et consentement : éclairage psychopathologique et sémiotique [Addiction and consent: psychopathological and semiotic point of view] (with English abstract). Le Courrier des Addictions 21 (2) 13-17.
- Humeau, E., Peyre, H., Pfau, G., Pitrat, B. and Maatoug, R. (2020). Multivisceral failure in a context of serotonin syndrome induced by MDMA: The investigation of a unique and nationwide network. Journal of Addiction Medicine 14 175-177.
- Lafaye, G., Desterke, C., Marulaz, L. and Benyamina, A. (2019). Cannabidiol affects circadian clock core complex and its regulation in microglia cells. Addiction Biology 24 (5) 921-934.
- Leclercq, M., Soichot, M., Delhotal-Landes, B., Bourgogne, E., Gurlain, H., Megarbane, B. *et al.* (2020). False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology. J Anal Toxicol 44 200-205.
- Mansouri-Guilani, N., Bernard, V., Vigneault, E., Vialou, V., Dumas, S., El Mestikawy, S. *et al.* (2019). VGLUT3 gates psychomotor effects induced by amphetamine. Journal of Neurochemistry 148 (6) 779-795.
- Marie, N., Canestrelli, C. and Noble, F. (2019). Role of pharmacokinetic and pharmacodynamic parameters in neuroadaptations induced by drugs of abuse, with a focus on opioids and psychostimulants. Neuroscience and Biobehavioral Reviews 106 217-226.
- Marion-Poll, L., Besnard, A., Longueville, S., Valjent, E., Engmann, O., Caboche, J. *et al.* (2019). Cocaine conditioned place preference: unexpected suppression of preference due to testing combined with strong conditioning. Addiction Biology 24 (3) 364-375.
- Noble, F. (2019). Circuits neuronaux et neuromédiateurs impliqués dans les effets des drogues psychoactives – État de l'art avec un focus sur la cocaïne [Neural circuits and neurotransmitters involved in the effects of psychoactive drugs – State of the art with a focus on cocaine] (with English abstract). Biologie Aujourd'hui 213 (3-4) 141-145.
- Noe, E., Bonneau, N., Fournier, M.L., Caille, S., Cador, M. and Le Moine, C. (2019). Arc reactivity in accumbens nucleus, amygdala and hippocampus differentiates cue over context responses

during reactivation of opiate withdrawal memory. Neurobiology of Learning and Memory 159 24-35.

Ramoz, N., Lacoste, J., Davido, G., Lamy, S., Ballon, N., Jehel, L. *et al.* (2020). Brief report: A positive association between the DAT1 gene and crack cocaine use disorders in a French Afro-Caribbean population. French Journal of Psychiatry 1 25-30.

Saad, L., Sartori, M., Pol Bodetto, S., Romieu, P., Kalsbeek, A., Zwiller, J. *et al.* (2019). Regulation of Brain DNA Methylation Factors and of the Orexinergic System by Cocaine and Food Self-Administration. Molecular Neurobiology 56 (8) 5315-5331.

Scheyer, A.F., Melis, M., Trezza, V. and Manzoni, O.J.J. (2019). Consequences of perinatal cannabis exposure. Trends in Neurosciences 42 (12) 871-884.

Soichot, M., Leclercq, M., Allard, M., Mihoubi, A., Gurlain, H., Bourgogne, E. *et al.* (2019). Intérêt d'une méthode enzymatique pour le diagnostic des intoxications par GHB/GBL [Usefulness of enzymatic method in the diagnosis of GHB/GBL poisoning] (with English abstract). Toxicologie Analytique et Clinique 31 (2) 106-115.

Tan, D., Nuno-Perez, A., Mameli, M. and Meye, F.J. (2019). Cocaine withdrawal reduces GABA(B)R transmission at entopeduncular nucleus - lateral habenula synapses. European Journal of Neuroscience 50 (3) 2124-2133.

Thiebault, T., Fougère, L., Destandau, E., Réty, M. and Jacob, J. (2019). Impact of meteorological and social events on human-excreted contaminant loads in raw wastewater: From daily to weekly dynamics. Chemosphere 230 107-116.

Tinta Struillou, H., Lemaire, C., Sculo Chaiban, T. and Guillou-Landreat, M. (2019). Addictions et problèmes bucco-dentaires [Addictions and oral problems] (with English abstract). Psychotropes 25 43-60.

Vandaele, Y., Vouillac-Mendoza, C. and Ahmed, S.H. (2019). Inflexible habitual decision-making during choice between cocaine and a nondrug alternative. Translational Psychiatry 9 (1) 109.

Verhaeghe, F., Di Pizio, P., Bichara, C., Berby, B., Rives, A., Jumeau, F. *et al.* (2020). Cannabis consumption might exert deleterious effects on sperm nuclear quality in infertile men. Reproductive Biomedicine Online 40 (2) 270-280.

(2) Population based and clinical epidemiology (including site surveys, ethnographic studies and acute toxicity studies)

Airagnes, G., Lemogne, C., Meneton, P., Plessz, M., Goldberg, M., Hoertel, N. *et al.* (2019). Alcohol, tobacco and cannabis use are associated with job loss at follow-up: Findings from the CONSTANCES cohort. PLoS One 14 (9) e0222361.

Barberot, P., Gibaja, V., Benkhedda, C., Dobre, D., Tournebize, J. and Kahn, J.P. (2019). Identification de cas d'abus/dépendance par le réseau français d'addictovigilance : une étude pilote du CEIP-A et du Centre psychothérapeutique de Nancy [Identification of abuse/dependence cases by the French addictovigilance network (FAN): A pilot study of the addictovigilance center and the psychotherapeutic center of Nancy] (with English abstract). Thérapie 74 (3) 389-397.

Batisse, A., Eiden, C., Peyriere, H. and Djeddar, S. (2020). Use of new psychoactive substances to mimic prescription drugs: the trend in France. NeuroToxicology 79 20-24.

Bénard-Larivière, A., Noize, P., Girodet, P.-O., Lassalle, R., Dureau-Poumin, C., Droz-Perroteau, C. *et al.* (2019). Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France. Thérapie 74 (4) 469-476.

- Bertin, C., Delorme, J., Riquelme, M., Peyriere, H., Brousse, G., Eschalier, A. *et al.* (2019) Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients. British Journal of Clinical Pharmacology, 10.1111/bcp.14082.
- Bonnaire, C., Beck, F. and Spilka, S. (2019). Physical and psychosocial factors associated with psychostimulant use in a nationally representative sample of French adolescents: Specificities of cocaine, amphetamine, and ecstasy use. Addictive Behaviors 92 208-224.
- Cadet-Taïrou, A., Brisacier, A.-C. and Martinez, M. (2019). Opioides : nouveaux produits et nouvelles tendances d'usage en France. Alcoologie et Addictologie 41 (3) 219-226.
- Coudert, C., Vidal, C., Lefevre, T. and Chariot, P. (2019). Adolescent arrestees detained in police cells: an observational study in the Paris, France, area. International Journal of Legal Medicine 133 (4) 1251-1258.
- Dassieu, L. (2019). L'automédication chez les usagers de drogues : de la constitution de savoirs expérientiels à leur confrontation aux médecins [Self-medication among drug users: from experiential knowledge to interaction with physicians] (with English abstract). Anthropologie et Santé (18).
- Delaye, M. and Soilihi Moulevou, L. (2019). Consommation de substances psychoactives à Mayotte. De la société traditionnelle à aujourd'hui, quel impact sur la prise en charge des jeunes ? (in French only). VST - Vie Sociale et Traitements (143) 120-125.
- Delignère, A.-L., Archambault, G., Chalvin, F., Perquier, F. and Lejoyeux, M. (2020). Schizophrénie et addictions : Étude exploratoire chez 106 patients suivis en consultation [Schizophrenia and addictions: Exploratory study among 106 patients followed in consultation] (with English abstract). Annales Médico-psychologiques, revue psychiatrique 178 226-232.
- Devault, D.A., Peyré, A., Jaupitre, O., Daveluy, A. and Karolak, S. (2020). The effect of the Music Day event on community drug use. Forensic Science International 309 110226.
- di Luzio, S.S., Procentese, F. and Guillet-Descas, E. (2019). Physical activity in adolescence and substance use: Factors of interdependence between local community and relational micro-systems. Journal of Child and Adolescent Substance Abuse 28 (2) 119-126.
- Dupui, M., Micallef, J. and Lapeyre-Mestre, M. (2019). Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution. Thérapie 74 (2) 307-314.
- Embersin-Kyprianou, C., Yermachenko, A., Massari, V., El-Khoury-Lesueur, F. and Melchior, M. (2020). Grossesses non prévues, violences sexuelles et contraception chez les femmes consommant du cannabis ou d'autres substances psychoactives illégales en Île-de-France : données du Baromètre Santé 2016 [Unexpected pregnancy, experience of sexual violence and contraception among women who use cannabis or other illegal substance in the Great Paris Region: Data from the 2016 Health Barometer] (with English abstract). Revue d'Epidémiologie et de Santé Publique 68 (1) 9-15.
- Fond, G., Bourbon, A., Boucekine, M., Messiaen, M., Barrow, V., Auquier, P. *et al.* (2020). First-year French medical students consume antidepressants and anxiolytics while second-years consume non-medical drugs. Journal of Affective Disorders 265 71-76.
- Gaissad, L. and Velter, A. (2019). Drogue et sexualité gay sous influence : « Quand on prend ça, c'est fait pour » [Drugs and gay sex under influence. "Getting high to get laid"] (full English translation available). Sexologies 28 (3) 128-134.
- Gandolphe, M.C., Duprez, C., Enault, F., Seyeux, O., Brunelle, E., Duparcq, J.P. *et al.* (2019). Compromises of integration, specificity and emotional content of self-defining memories in patients with opioid-use disorder. Memory 27 (5) 637-646.

- Guidet, C., Gregoire, M., Le Dreau, A., Vrignaud, B., Deslandes, G. and Monteil-Ganiere, C. (2020). Cannabis intoxication after accidental ingestion in infants: urine and plasma concentrations of Delta-9-tetrahydrocannabinol (THC), THC-COOH and 11-OH-THC in 10 patients. Clinical Toxicology 58 421-423.
- Hartley, S., Simon, N., Larabi, A., Vaugier, I., Barbot, F., Quera-Salva, M.A. *et al.* (2019). Effect of smoked cannabis on vigilance and accident risk using simulated driving in occasional and chronic users and the pharmacokinetic-pharmacodynamic relationship. Clinical Chemistry 65 (5) 684-693.
- Janssen, E., Cadet-Taïrou, A., Gérome, C. and Vuolo, M. (2020). Estimating the size of crack cocaine users in France: Methods for an elusive population with high heterogeneity. International Journal of Drug Policy 76 102637.
- Larabi, I.A., Fabresse, N., Etting, I., Nadour, L., Pfau, G., Raphalen, J.H. *et al.* (2019). Prevalence of New Psychoactive Substances (NPS) and conventional drugs of abuse (DOA) in high risk populations from Paris (France) and its suburbs: A cross sectional study by hair testing (2012-2017). Drug and Alcohol Dependence 204 107508.
- Lepez, C., Mehtelli, W., Azuar, J., Bellivier, F. and Vorspan, F. (2019). Caractéristiques des usagers de cannabis dans un cabinet de médecine générale en France [Characteristics of cannabis users in a French family practice] (with English abstract). Revue d'Epidémiologie et de Santé Publique 67 (3) 175-180.
- Marchi, J., Mayet, A., Chamonaz, C., de Laval, F., Paul, F. and Marimoutou, C. (2019). Differential impact according to mission's operational intensity on psychoactive substance use: A retrospective cohort of French male army service members. Substance Use and Misuse 54 (5) 841-851.
- Marchin, É., Marty, F. and Gaudriault, P. (2020). L'expérience addictive comme métaphore d'un fonctionnement extraordinaire [The experience of addiction as a metaphor for an extraordinary way of functioning] (with English abstract). Adolescence 38 (1) 39-50.
- Martin, H., Bursztejn, A.C., Albuisson, E., Leguem, A., Mahe, E., Villemur, B. *et al.* (2019). Caractéristiques des plaies chroniques chez les toxicomanes : étude rétrospective de 58 patients [Characteristics of chronic wounds in substance abuse: A retrospective study of 58 patients] (with English abstract). Annales de Dermatologie et de Vénérologie 146 (12) 793-800.
- Mezaache, S., Briand-Madrid, L., Laporte, V., Mora, M., Moudachirou, K., Rojas Castro, D. *et al.* (2020). Correlates of self-reported cotton fever experience among people who inject opioids. Substance Use and Misuse 55 (6) 1021-1027.
- Micallef, J., Jouanjus, E., Mallaret, M. and Lapeyre-Mestre, M. (2019). Détection des signaux du réseau français d'addictovigilance : méthodes innovantes d'investigation, illustrations et utilité pour la santé publique [Safety signal detection by the French Addictovigilance Network: Innovativemethods of investigation, examples and usefulness for public health] (with English abstract). Thérapie 74 (6) 579-590.
- Noel, G.N., Maghoo, A.M., Franke, F.F., Viudes, G.V. and Minodier, P.M. (2019). Increase in emergency department visits related to cannabis reported using syndromic surveillance system. European Journal of Public Health 29 (4) 621-625.
- Richeval, C., Dumestre-Toulet, V., Wiart, J.-F., Vanhoye, X., Humbert, L., Nachon-Phanithavong, M. *et al.* (2019). New psychoactive substances in oral fluid of drivers around a music festival in south-west France in 2017. Forensic Science International 297 265-269.
- Robin, C. (2019). La santé psychique des internes en psychiatrie de France et leurs consommations de substances psychoactives. Étude épidémiologique transversale descriptive [Mental health and psychoactive substance use among psychiatry interns in France: A descriptive and epidemiological cross-sectional study] (with English abstract). L'Information Psychiatrique 95 (7) 559-568.

Rousselet, M., Guerlais, M., Caillet, P., Le Geay, B., Mauillon, D., Serre, P. *et al.* (2019). Consumption of psychoactive substances in prison: Between initiation and improvement, what trajectories occur after incarceration? COSMOS study data. PLoS One 14 (12) e0225189.

Santos, M.E., Protopopescu, C., Sogni, P., Yaya, I., Piroth, L., Bailly, F. *et al.* (2020). HCV-related mortality among HIV/HCV co-infected patients: The importance of behaviors in the HCV cure era (ANRS CO13 HEPAVIH Cohort). AIDS and Behavior 24 1069-1084.

Serra, W., Chatard, A., Tello, N., Harika-Germaneau, G., Noel, X. and Jaafari, N. (2019). Mummy, Daddy, and addiction: Implicit insecure attachment is associated with substance use in college students. Experimental and Clinical Psychopharmacology 27 (6) 522-529.

Underner, M., Peiffer, G., Perriot, J. and Jaafari, N. (2020). Complications pulmonaires chez les consommateurs de cocaïne [Pulmonary complications in cocaine users] (with English abstract). Revue des Maladies Respiratoires 37 (1) 45-59.

Underner, M., Perriot, J., Peiffer, G., Urban, T. and Jaafari, N. (2020). Pneumonies aiguës à éosinophiles et usage de substances psychoactives illicites [Acute eosinophilic pneumonia and illicit psychoactive substance use] (with English abstract). Revue des Maladies Respiratoires 37 (1) 34-44.

(3) Demand reduction (including prevention, treatment, harm reduction, reintegration and clinical treatment research)

Bazin, A.-S. (2019). La thérapie de Pleine Conscience : une médiation articulant les espaces psychiques et corporels. Reflet d'une pratique à l'hôpital Marmottan [The Mindfulness Therapy: a mediation articulating the psychic and corporal spaces] (with English abstract). Psychotropes 25 (2) 11-29.

Boyer, C. (2019). Dispositifs de soins addictologiques en psychiatrie : état des lieux en France [Addictology health care systems in psychiatry: state of play in France] (with English abstract). Le Courrier des Addictions 21 (2) 8-12.

D'Abbadie de Nodrest, L. and Sudres, J.-L. (2019). Musicothérapie et polyaddiction : du lien culturellement établi à la proposition d'un dispositif, en centre de soins, d'accompagnement et de prévention en addictologie [Music therapy and poly-addiction: From a culturally established link to a proposed system of accompaniment and prevention in addiction care centers] (with English abstract). Bulletin de psychologie 115-127.

Delile, J.-M. (2019). Espace(s) de la salle de consommation à moindre risque, entre dedans et dehors [Low risk drug consumption rooms, between inside and outside] (with English abstract). Alcoologie et Addictologie 41 (3) 210-218.

Dematteis, M., Auriacombe, M., D'Agnone, O., Somaini, L., Szerman, N., Littlewood, R. *et al.* (2019). Recommandations pour le traitement du trouble de l'usage des opioïdes par la buprénorphine et la méthadone. Consensus européen [Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus] (with English abstract). Alcoologie et Addictologie 41 (4) 336-354.

Dugarin, J. (2019). L'addictologie : d'une néo-discipline et de son homogénéité. Conditions de production des savoirs à l'oeuvre [Addictology: a neo-discipline and its homogeneity. Conditions for knowledge generation at work] (with English abstract). Psychotropes 25 9-22.

Fernandes Pereira, P. (2019). Psychothérapie(s) et addiction(s) : enveloppes, attachement et relations interpersonnelles. Psychotropes 25 23-41.

Forrat, C. (2020). Violence, addictions et émotions : étude d'un dispositif groupal métaphorique (in French only). Le Journal des psychologues (374) 74-78.

- Frauger, E., Sam-Laï, N.F., Mallaret, M., Micallef, J. and French Addictovigilance Network (FAN) (2019). Améliorer la balance bénéfiques/risques de la méthadone en respectant ses spécificités pharmacologiques [Improve the benefit/risk balance of methadone by respecting its pharmacological specificities] (with English abstract). Thérapie 74 (3) 383-388.
- Goujat, R. (2020). La place du psychologue dans la prise en charge addictologique [The place of the psychologist in an addiction care] (with English abstract). Soins Psychiatrie 41 (326) 20-23.
- Jenny, O., Dubosc, D., Zannoni, E. and Cheval, C. (2020). Sensibilisation à l'addictologie et collaboration avec les personnels hospitaliers. L'expérience d'une équipe de liaison [Sensitization to addictology and collaboration with hospital caregivers. Experience of a liaison-team] (with English abstract). Annales Médico-psychologiques, revue psychiatrique 178 (4) 384-388.
- Klitting, B. (2019). Évaluation du traitement ostéopathique pour les symptômes dus au sevrage toxicologique [Assessment of osteopathic treatments for pathologies due to toxicological withdrawal] (with English abstract). Psychotropes 25 (2) 57-90.
- Laqueille, X. and Lucet, C. (2020). Aspects cliniques et positionnement thérapeutique en addictologie [Clinical aspects and therapeutic positioning in addictology] (with English abstract). Soins Psychiatrie 41 (326) 12-15.
- Laqueille, X. and Richa, S. (2019). Le positionnement thérapeutique en addictologie. Quelques réflexions à partir de la pratique (in French only). Laennec 67 (2) 30-40.
- Lenglard, F., Berger-Vergiat, A., Ragonnet, D., Duvemay, N., Lack, P., Poulet, E. *et al.* (2019). Retour d'expérience de deux CSAPA et enquête nationale sur la naloxone intranasale (Nalscue®) dans la prévention des overdoses aux opioïdes [Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue®) in the prevention of opioid overdoses] (with English abstract). Thérapie 74 (4) 477-486.
- Mehdaoui, Y. (2019). Addictions et pratique du shiatsu [Addictions and practice of shiatsu] (with English abstract). Psychotropes 25 (2) 51-56.
- Muller, O., Baumann, C., Di Patrizio, P., Viennet, S., Vlamynck, G., Collet, L. *et al.* (2020). Patient's early satisfaction with care: a predictor of health-related quality of life change among outpatients with substance dependence. Health and Quality of Life Outcomes 18 6-6.
- Nabbout, R. and Thiele, E.A. (2020). The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials. Epileptic Disorders 22 S23-S28.
- Nguyen-Xuan, D., Ancelin, D. and Héron, A. (2020). Thérapies corps-esprit en addictologie : apports de la psychomotricité [Body-mind therapies in addictology: contributions of psychomotricity] (with English abstract). Soins Psychiatrie 41 (326) 30-34.
- Renard, O., Corbin, S., Drouet, Y., Lasset, C. and Chvetzoff, G. (2019). Cannabis et prise en charge antalgique : quelles conséquences sur la prescription d'opioïdes forts ? Étude observationnelle au centre Léon-Bérard d'une population de patients atteints d'un cancer du poumon [Cannabis and Analgesic Management: What Are the Consequences for the Prescription of Strong Opioids? Observational Study at the Léon-Bérard Center in a Lung Cancer Patients Cohort] (with English abstract). Douleur et Analgésie 32 (2) 82-86.
- Revol, A. (2019). Prescription de cannabis à usage thérapeutique pour les personnes âgées atteintes de démence : l'engouement des proches aidants [Medical cannabis for elderly people with dementia : family caregivers' enthusiasm] (with English abstract). Psychotropes 25 (2) 129-149.
- Reynaud, M.-A. (2019). Le travail sur les enveloppes psychocorporelles en psychomotricité chez le sujet addict [Essay on psycho-corporal membranes in psychomotricity on addict patients] (with English abstract). Psychotropes 25 (2) 113-127.

- Roberts, D. (2019). Hypnose et addictions [Hypnosis and addictions] (with English abstract). Psychotropes 25 (2) 91-103.
- Rojas Rojas, T., Di Beo, V., Delorme, J., Barre, T., Mathurin, P., Protopopescu, C. *et al.* (2019). Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. International Journal of Drug Policy 72 61-68.
- Royer, S., Di Patrizio, P., Baumann, C., Chapron, A., Viennet, S., Clerc-Urmès, I. *et al.* (2019). Satisfaction précoce vis-à-vis des soins ambulatoires chez des patients dépendants aux substances psychoactives [Early satisfaction with care among outpatients with substance dependence] (with English abstract). L'Encéphale 45 (4) 333-339.
- Scroccaro, N. and Sierra Rubio, M.A. (2020). Le concept de compensation en addictologie [The concept of compensation in addictology] (with English abstract). Annales Médico-psychologiques, revue psychiatrique 178 245-250.
- Selponi, Y. (2019). Apprendre les drogues en classe. La construction sociale des psychotropes par leurs effets lors des actions de prévention des conduites addictives en milieu scolaire (in French only). Agora débats/jeunesses (81) 109-121.
- Simart, S. (2020). Dépister les psychotraumatismes chez les personnes ayant une problématique addictive [Identify psychotraumatism in people with addictive problems] (with English abstract). Soins Psychiatrie 41 (326) 24-29.
- Suarez, B. (2019). Hypnose, activation de conscience et nouvelles solutions thérapeutiques des addictions : aspects neurobiologiques [Hypnosis, activation of consciousness and new therapeutic solutions for addictions: neurobiological aspects] (with English abstract). Psychotropes 25 (2) 105-111.
- Touzeau, D., Pascuttini, F., Bard De Siquera, E. and Deschenau, A. (2019). Buprénorphine à action prolongée, un nouveau souffle pour la prise en charge des usagers d'opioïdes ? (with English abstract). Le Courrier des Addictions 21 (3) 11-15.
- Trouvin, A.P. and Perrot, S. (2019). Cannabis : enjeux et risques en médecine de la douleur [Cannabis: a major challenge in pain medicine] (with English abstract). Douleur et Analgésie 32 (2) 73-78.
- Vayr, F., Herin, F., Jullian, B., Soulat, J.M. and Franchitto, N. (2019). Barriers to seeking help for physicians with substance use disorder: A review. Drug and Alcohol Dependence 199 116-121.
- von Hammerstein, C. and Romo, L. (2019). Réflexions sur la pleine conscience et l'autocompassion pour le traitement des addictions [Reflections on mindfulness and self-compassion for the treatment of addictions] (with English abstract). Psychotropes 25 (2) 31-49.

(4) Supply, supply reduction and crime

- Catonné, J.-P. and Sanchez, J.-N. (2019). La mondialisation de la drogue, un espace politique. Savoir/Agir (50) 7-13.
- Weinberger, D., Gandilhon, M., Shah, J. and Lalam, N. (2019). Illegal cannabis cultivation in Europe: new developments. EchoGéo (48).

(5) Drug policy (including laws, economic issues and strategies)

- Auriol, E. and Geoffard, P.-Y. (2019). Cannabis : comment reprendre le contrôle ? Savoir/Agir (50) 51-60.

- Colson, R. (2019). Le régime international de contrôle des drogues. Passé, présent et avenir. Savoir/Agir (50) 43-49.
- Curtet, F. (2019). Toxicomanies : silence, on gère ! Savoir/Agir (50) 61-66.
- Goullé, J.-P. and Morel, F. (2020). Consommation de drogues licites et illicites chez l'adolescent : une situation alarmante qui impose une prévention précoce. Rapport 19-09 [Use of licit and illicit drugs in teenagers: an alarming situation, which requires early prevention] (with English abstract). Bulletin de l'Académie Nationale de Médecine 204 (1) 4-15.
- Laurent, A., Garaudel, P., Schmidt, G. and Eynaud, P. (2020). Civil society meta-organizations and legitimating processes: The case of the addiction field in France. Voluntas 31 (1) 19-38.
- Melchior, M., Nakamura, A., Bolze, C., Hausfater, F., El Khoury, F., Mary-Krause, M. *et al.* (2019). Does liberalisation of cannabis policy influence levels of use in adolescents and young adults? A systematic review and meta-analysis. BMJ Open 9 (7) e025880.
- Obradovic, I. (2019) From prohibition to regulation: A comparative analysis of the emergence and related outcomes of new legal cannabis policy models (Colorado, Washington State and Uruguay). International Journal of Drug Policy 102590, 10.1016/j.drugpo.2019.11.002.
- Samuel, M., Benoit, M. and Abou, N.N. (2019). Expertise psychiatrique : quelle est la responsabilité pénale en cas de consommation de cannabis ? [Psychiatric expertise: What is the criminal responsibility for cannabis use?] (with English abstract). Annales Médico-psychologiques, revue psychiatrique 177 (4) 327-334.

T4. Additional information

The purpose of this section is to provide additional information important to drug-related research in your country that has not been provided elsewhere.

- T4.1. **Optional.** Please describe any additional important sources of information, specific studies or information on drug-related research priorities. Where possible, please provide references and/or links.

- T4.2. **Optional.** Please describe any other important aspect of drug-related research that has not been covered in the specific questions above. This may be additional information, a reference to an organisation in your country that monitors national drug-related research, the availability of a bibliography of recent studies or new areas of specific importance for your country.

T5. Sources and methodology

The purpose of this section is to collect sources and bibliography for the information provided above, including brief descriptions of studies and their methodology where appropriate.

- T5.1. Please list notable sources for the information provided above.

MILDECA (2018). Alcool, tabac, drogues, écrans : Plan national de mobilisation contre les addictions 2018-2022 [Alcohol, tobacco, drugs, screens: National plan for mobilisation against addictions 2018-2022]. Mission interministérielle de lutte contre les drogues et les conduites addictives, Paris. Available: <https://www.drogues.gouv.fr/la-mildeca/le-plan-gouvernemental/mobilisation-2018-2022> [accessed 10/08/2020].